



## SEQUENCE LISTING

<110> OZAWA, Keiya  
SHIMPO, Masahisa  
IKEDA, Uichi  
MAEDA, Yoshikazu  
SHIMADA, Kazuyuki

<120> ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC  
FACTORS

<130> 0800-0026

<140> 09/932,451

<141> 2001-08-17

<150> 60/226,056

<151> 2000-08-17

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 576

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF-165

<220>

<221> CDS

<222> (1)..(576)

<400> 1

atg aac ttt ctg ctg tct tgg gtg cat tgg agc ctt gcc ttg ctg ctc	48
Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu	
1 5 10 15	

tac ctc cac cat gcc aag tgg tcc cag gct gca ccc atg gca gaa gga	96
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly	
20 25 30	

gga ggg cag aat cat cac gaa gtg gtg aag ttc atg gat gtc tat cag	144
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln	
35 40 45	

cgc agc tac tgc cat cca atc gag acc ctg gtg gac atc ttc cag gag	192
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu	
50 55 60	

tac cct gat gag atc gag tac atc ttc aag cca tcc tgt gtg ccc ctg	240
---	-----

atg cga tgc ggg ggc tgc tgc aat gac gag ggc ctg gag tgt gtg ccc 288  
 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
                     85                    90                    95

act gag gag tcc aac atc acc atg cag att atg cgg atc aaa cct cac 336  
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
                     100                    105                    110

caa ggc cag cac ata gga gag atg agc ttc cta cag cac aac aaa tgt 384  
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
                     115                    120                    125

gaa tgc aga cca aag aaa gat aga gca aga caa gaa aat ccc tgt ggg 432  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly  
                     130                    135                    140

cct tgc tca gag cgg aga aag cat ttg ttt gta caa gat ccg cag acg 480  
 Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr  
                     145                    150                    155                    160

tgt aaa tgt tcc tgc aaa aac aca gac tgc cgt tgc aag gcg agg cag 528  
 Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln  
                     165                    170                    175

ctt gag tta aac gaa cgt act tgc aga tgt gac aag ccg agg cgg tga 576  
 Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg  
                     180                    185                    190

<210> 2

<211> 191

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF-165

<400> 2

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
           1                    5                    10                    15

Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
                     20                    25                    30

Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln  
                     35                    40                    45

Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
                     50                    55                    60

Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
                     65                    70                    75                    80

Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
 115 120 125

Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly  
 130 135 140

Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr  
 145 150 155 160

Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln  
 165 170 175

Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg  
 180 185 190

<210> 3  
 <211> 22  
 <212> DNA  
 <213> VEGF-specific sense primer

<400> 3  
 GAGGGCAGAA TCATCACGAA GT 22

<210> 4  
 <211> 20  
 <212> DNA  
 <213> VEGF-specific antisense primer

<400> 4  
 CCACCTTCTT GATGTCATCA 20